Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748040 · ClinicalTrials.gov registry record · NA
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 1,874
- Enrollment target
NCT06748040: Completed NA study, sponsored by Duke University.
NCT06748040 is a NA study that has completed, run by Duke University. The registered enrollment target is 1,874 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06748040, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,874 participants
- Enrollment target
Study Summary
This is a substudy of GUARDD-US (Genetic testing to Understand and Address Renal Disease Disparities across the United States, NCT04191824). Its primary purpose is to determine the effect of knowledge of genetic test results that predict efficacy of various antihypertensive medications on change in SBP (systolic blood pressure) from baseline to 3 months in APOL1 (apolipoprotein L1) negative individuals at participating sites.
Interventions
- OTHER Timing of return of results
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,874 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2024-05-17 |
| Phase | NA |
What the finished NCT06748040 record still lists
NCT06748040 is an interventional study that assigns participants to a tested intervention. Its 1,874 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 1 intervention - of which Timing of return of results is the first listed.
NCT06748040 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06748040 about?
NCT06748040 is a clinical study titled "Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy". This is a substudy of GUARDD-US (Genetic testing to Understand and Address Renal Disease Disparities across the United States, NCT04191824). Its primary purpose is to determine the effect of knowledge of genetic test results that predict efficacy of various antihypertensive medications on change in ...
What is the current status of trial NCT06748040?
This trial is currently completed. It is a NA study. The enrollment target is 1,874 participants. The study started on 2020-07-10. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT06748040?
The interventions under investigation include: Timing of return of results (OTHER).
Who is sponsoring clinical trial NCT06748040?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06748040's enrollment target sits among peer trials
1,874 56th of 2000 higher than 1,945 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT06891898 · 1,875 participants
The iLet Experience Study
- NCT07356089 · 1,875 participants
Twiist Postmarket Surveillance Study for Type 1 Diabetes
- NCT07203313 · 1,872 participants · NA
Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI